FDA Approves Depo-Provera Brain Tumor Warning Label Update

The Food and Drug Administration (FDA) has approved a label change for Pfizer’s birth control shot Depo-Provera, adding a warning about the potential risk of meningioma, a tumor that forms in the tissue surrounding the brain and spinal cord. This regulatory action comes amid mounting litigation from over 2,000 women who claim that Pfizer knew about the alleged Depo-Provera brain tumor risk but failed to properly warn patients.

Alleged Depo-Provera Meningioma Brain Tumor Risk

Depo-Provera, a quarterly injectable contraceptive containing medroxyprogesterone acetate (MPA), has been used by approximately 25% of sexually active women in the United States, according to Centers for Disease Control and Prevention (CDC) data from 2023. 

However, a growing body of research on the potential risk of brain tumors from Depo-Provera has raised concerns about the medication’s safety profile. In a 2024 study published in the British Medical Journal, women who received Depo-Provera injections for longer than one year had a 5.6-fold increased risk of developing meningiomas compared to those not using the contraceptive. 

What are Meningioma Brain Tumors?

Meningioma brain tumors, while typically non-cancerous, can cause serious health complications depending on their size and location within the brain. They affect approximately 39,000 Americans annually, and symptoms may include persistent headaches, vision changes, seizures, and other neurological disturbances that can significantly impact quality of life. In severe cases, surgical intervention becomes necessary, potentially leading to long-term health consequences.

Timeline of Depo-Provera Warning Label Updates

The FDA’s decision to approve the addition of a brain tumor warning on the Depo-Provera label represents a notable reversal from its earlier position. In February 2024, Pfizer submitted an application requesting permission to update Depo-Provera’s label with meningioma warnings. Regulators initially denied this request, stating that available observational studies did not sufficiently support adding such warnings. 

Following additional data submission and review, Pfizer amended and resubmitted its application in June 2025. The FDA ultimately approved the warning in December 2025, requiring label updates for both Depo-Provera CI and Depo-SubQ Provera 104 formulations.

The newly approved warning states: “Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use. Monitor patients on Depo-Provera CI for signs and symptoms of meningioma. Discontinue Depo-Provera CI if a meningioma is diagnosed.”

Disparities in International Depo-Provera Warnings

One troubling aspect of this Depo-Provera label update involves the significant delay in warning American women compared to their international counterparts. Health authorities in Canada and the European Union implemented meningioma warnings for Depo-Provera users as early as 2022, three years before similar protections reached American patients.

In 2024, the European Medicines Agency formally classified meningioma as a “possible side effect” of medications containing high-dose medroxyprogesterone acetate. That same year, Canadian health officials updated their labeling to explicitly warn that “meningiomas have been reported following long-term administration of progestins, including medroxyprogesterone acetate.”

South African regulatory authorities followed suit in January 2025, recommending similar warning updates. This international consensus on the potential brain tumor risk from Depo-Provera makes the delayed implementation of warnings in the United States particularly concerning for patient advocates.

Depo-Provera Brain Tumor Lawsuits and Allegations

Depo-Provera maker Pfizer currently faces over 2,000 lawsuits from women who developed meningiomas allegedly linked to Depo-Provera use. Many of these legal claims have been consolidated in multidistrict litigation (MDL) before Judge M. Casey Rodgers in the Northern District of Florida.

Plaintiffs’ attorneys argue that scientific evidence linking progesterone and meningiomas dates back to 1983, and that the company should have studied these alleged side effect risks more thoroughly and provided appropriate warnings much earlier.

In court filings, Pfizer has maintained that it only became aware of potential meningioma risks associated with Depo-Provera in 2023 and acted promptly by submitting label change requests to the FDA. The company continues to defend the safety and efficacy of the medication.

What This Means for Depo-Provera Users

The warning label update represents a significant development for current and former Depo-Provera users. Women who have experienced persistent headaches, vision changes, or other neurological symptoms should consult their healthcare provider, particularly if they have used the contraceptive for extended periods.

For those already diagnosed with meningiomas, the label change may provide important context for understanding potential contributing factors to their condition. The warning advises healthcare providers to monitor patients for meningioma symptoms and discontinue the medication if such tumors are diagnosed.

For women considering contraceptive options, this new Depo-Provera warning underscores the importance of discussing potential risks and benefits with healthcare providers. The label update allows for more informed decision-making about reproductive health choices and emphasizes the need for vigilance regarding the potential side effects of pharmaceutical drugs.